U.S. markets open in 6 hours 2 minutes

Have Insiders Been Buying CorMedix, Inc. (NYSEMKT:CRMD) Shares This Year?

Simply Wall St

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell CorMedix, Inc. (NYSEMKT:CRMD), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, most countries require that the company discloses such transactions to the market.

Insider transactions are not the most important thing when it comes to long-term investing. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

See our latest analysis for CorMedix

The Last 12 Months Of Insider Transactions At CorMedix

Executive Vice President for Technical Operations John Armstrong made the biggest insider purchase in the last 12 months. That single transaction was for US$363k worth of shares at a price of US$7.26 each. That means that an insider was happy to buy shares at above the current price of US$6.14. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

In the last twelve months CorMedix insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

AMEX:CRMD Recent Insider Trading, October 24th 2019

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

CorMedix Insiders Bought Stock Recently

It's good to see that CorMedix insiders have made notable investments in the company's shares. Not only was there no selling that we can see, but they collectively bought US$182k worth of shares. That shows some optimism about the company's future.

Insider Ownership of CorMedix

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests CorMedix insiders own 1.9% of the company, worth about US$3.0m. We consider this fairly low insider ownership.

What Might The Insider Transactions At CorMedix Tell Us?

It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that CorMedix insiders are expecting a bright future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for CorMedix.

Of course CorMedix may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.